# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-22-037402
Filing Date
2022-10-17
Accepted
2022-10-17 16:18:20
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20005397x3_defa14a.htm | DEFA14A | 11884
2 |  | ny20005397x3_nc1.jpg | GRAPHIC | 1869421
3 |  | ny20005397x3_nc2.jpg | GRAPHIC | 1171596
| Complete submission text file | 0001140361-22-037402.txt |  | 3918895

Mailing Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105
Business Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105 734-335-0468
ENDRA Life Sciences Inc. (Filer) CIK: 0001681682 (see all company filings)

EIN.: 260579295 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37969 | Film No.: 221313925
SIC: 3845 Electromedical & Electrotherapeutic Apparatus